John David Matthews, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Galantamine | 2 | 2013 | 33 | 0.710 |
Why?
|
| Electroconvulsive Therapy | 3 | 2013 | 505 | 0.520 |
Why?
|
| Amnesia, Anterograde | 1 | 2013 | 20 | 0.440 |
Why?
|
| Nootropic Agents | 1 | 2013 | 159 | 0.400 |
Why?
|
| Depressive Disorder, Major | 8 | 2013 | 4805 | 0.330 |
Why?
|
| Health Care Rationing | 1 | 2011 | 435 | 0.290 |
Why?
|
| Fluoxetine | 5 | 2010 | 731 | 0.280 |
Why?
|
| Citalopram | 1 | 2009 | 402 | 0.260 |
Why?
|
| Adoption | 1 | 2006 | 97 | 0.250 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2007 | 242 | 0.250 |
Why?
|
| Quinolones | 1 | 2009 | 387 | 0.250 |
Why?
|
| Homosexuality | 1 | 2006 | 268 | 0.240 |
Why?
|
| Psychotic Disorders | 4 | 2013 | 3274 | 0.240 |
Why?
|
| Social Work | 1 | 2006 | 158 | 0.230 |
Why?
|
| Antipsychotic Agents | 2 | 2009 | 3075 | 0.200 |
Why?
|
| Pirenzepine | 1 | 2002 | 115 | 0.200 |
Why?
|
| Health Care Reform | 1 | 2011 | 1257 | 0.190 |
Why?
|
| Prejudice | 1 | 2006 | 567 | 0.190 |
Why?
|
| Parenting | 1 | 2006 | 708 | 0.170 |
Why?
|
| Piperazines | 1 | 2009 | 2546 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2011 | 3270 | 0.140 |
Why?
|
| Cognition Disorders | 1 | 2007 | 3965 | 0.110 |
Why?
|
| Psychiatric Department, Hospital | 2 | 2003 | 133 | 0.100 |
Why?
|
| Antidepressive Agents | 1 | 2000 | 2901 | 0.070 |
Why?
|
| Neuropsychological Tests | 2 | 2013 | 7116 | 0.070 |
Why?
|
| Neuromuscular Depolarizing Agents | 1 | 2007 | 44 | 0.070 |
Why?
|
| Succinylcholine | 1 | 2007 | 67 | 0.070 |
Why?
|
| Inpatients | 2 | 2013 | 2563 | 0.070 |
Why?
|
| Depression | 3 | 2002 | 8223 | 0.070 |
Why?
|
| Suicidal Ideation | 1 | 2016 | 1465 | 0.060 |
Why?
|
| Affect | 1 | 2013 | 1494 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2013 | 6013 | 0.060 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2002 | 490 | 0.050 |
Why?
|
| Personality Disorders | 2 | 2009 | 727 | 0.050 |
Why?
|
| Patient Compliance | 2 | 2002 | 2693 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2013 | 12417 | 0.050 |
Why?
|
| Patient Dropouts | 1 | 2002 | 411 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 6306 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2007 | 1516 | 0.040 |
Why?
|
| Male | 12 | 2016 | 363815 | 0.030 |
Why?
|
| Benzodiazepines | 1 | 2002 | 1136 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2002 | 8037 | 0.030 |
Why?
|
| Female | 12 | 2016 | 396141 | 0.030 |
Why?
|
| Cognition | 1 | 2013 | 7043 | 0.030 |
Why?
|
| Middle Aged | 10 | 2016 | 223016 | 0.030 |
Why?
|
| Humans | 16 | 2016 | 765926 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2007 | 8724 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2007 | 15878 | 0.020 |
Why?
|
| Adult | 9 | 2016 | 223088 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 41680 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2002 | 3477 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2002 | 3712 | 0.020 |
Why?
|
| Length of Stay | 1 | 2003 | 6486 | 0.020 |
Why?
|
| Mental Disorders | 2 | 2003 | 6870 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2016 | 65194 | 0.010 |
Why?
|
| Prevalence | 2 | 2010 | 15828 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2003 | 24275 | 0.010 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2009 | 1987 | 0.010 |
Why?
|
| Adolescent | 3 | 2009 | 88811 | 0.010 |
Why?
|
| Aged | 5 | 2009 | 171163 | 0.010 |
Why?
|
| Outpatients | 1 | 2009 | 1595 | 0.010 |
Why?
|
| Social Isolation | 1 | 2002 | 366 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 2474 | 0.010 |
Why?
|
| Efficiency, Organizational | 1 | 2002 | 695 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2003 | 788 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2002 | 59496 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2002 | 2269 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 2844 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2002 | 2653 | 0.010 |
Why?
|
| Remission Induction | 1 | 2002 | 2413 | 0.010 |
Why?
|
| Young Adult | 2 | 2016 | 59857 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 3430 | 0.010 |
Why?
|
| Age Factors | 2 | 2002 | 18382 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2002 | 1512 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2002 | 2717 | 0.010 |
Why?
|
| Patient Participation | 1 | 2002 | 1447 | 0.010 |
Why?
|
| Forecasting | 1 | 2002 | 2936 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 7236 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 8522 | 0.010 |
Why?
|
| Boston | 1 | 2003 | 9334 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 10727 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 8492 | 0.010 |
Why?
|
| Research Design | 1 | 2002 | 6204 | 0.000 |
Why?
|
| Incidence | 1 | 2002 | 21513 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 39228 | 0.000 |
Why?
|
| Time Factors | 1 | 2002 | 40097 | 0.000 |
Why?
|
| Risk Factors | 1 | 2002 | 74850 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2003 | 81537 | 0.000 |
Why?
|
| United States | 1 | 2002 | 72909 | 0.000 |
Why?
|